Sterling Capital Management LLC reduced its holdings in Repligen Corporation (NASDAQ:RGEN – Free Report) by 87.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,536 shares of the biotechnology company’s stock after selling 10,547 shares during the period. Sterling Capital Management LLC’s holdings in Repligen were worth $295,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently made changes to their positions in the business. Farther Finance Advisors LLC increased its holdings in Repligen by 35.5% in the third quarter. Farther Finance Advisors LLC now owns 374 shares of the biotechnology company’s stock valued at $72,000 after purchasing an additional 98 shares during the last quarter. ABS Investment Management LLC bought a new stake in Repligen in the second quarter valued at approximately $191,016,000. State of Alaska Department of Revenue raised its holdings in Repligen by 2.9% in the third quarter. State of Alaska Department of Revenue now owns 5,346 shares of the biotechnology company’s stock worth $1,027,000 after purchasing an additional 150 shares during the period. Crossmark Global Holdings Inc. raised its holdings in Repligen by 3.5% in the third quarter. Crossmark Global Holdings Inc. now owns 4,525 shares of the biotechnology company’s stock worth $870,000 after purchasing an additional 152 shares during the period. Finally, Yousif Capital Management LLC raised its stake in Repligen by 1.3% during the 3rd quarter. Yousif Capital Management LLC now owns 12,604 shares of the biotechnology company’s stock worth $2,423,000 after buying an additional 160 shares during the period. Institutional investors own 97.64% of the company’s stock.
Repligen Trading Down 6.2%
RGEN stock opened at $176.94 on Friday. Repligen Corporation has a 52 week low of $100.99 and a 52 week high of $198.87. The company has a market capitalization of $9.99 billion, a PE ratio of 92.47, a price-to-earnings-growth ratio of 3.42 and a beta of 1.08. The company’s 50-day simple moving average is $178.05 and its 200 day simple moving average is $145.23. The company has a debt-to-equity ratio of 0.27, a quick ratio of 7.64 and a current ratio of 9.88.
Repligen (NASDAQ:RGEN – Get Free Report) last issued its earnings results on Tuesday, October 27th. The biotechnology company reported $0.53 EPS for the quarter, beating the consensus estimate of $0.46 by $0.07. Repligen had a negative net margin of 1.47% and a positive return on equity of 5.49%. The company had revenue of $209.31 million during the quarter, compared to analysts’ expectations of $206.70 million. During the same period in the previous year, the company earned $0.46 EPS. The business’s revenue for the quarter was up 10.9% compared to the same quarter last year. As a group, sell-side analysts anticipate that Repligen Corporation will post 2.07 earnings per share for the current year.
Wall Street Analyst Weigh In
Several equities analysts have recently weighed in on the company. UBS Group reiterated a “buy” rating on shares of Repligen in a report on Tuesday, September 29th. Weiss Ratings upgraded shares of Repligen from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, October 8th. Benchmark raised shares of Repligen from a “hold” rating to a “buy” rating and set a $185.00 price objective for the company in a research report on Tuesday, July 7th. Canaccord Genuity Group boosted their price objective on shares of Repligen from $145.00 to $180.00 and gave the company a “hold” rating in a research report on Monday, October 19th. Finally, Wells Fargo & Company increased their target price on Repligen from $180.00 to $185.00 and gave the stock an “overweight” rating in a report on Thursday, July 30th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Repligen currently has an average rating of “Moderate Buy” and a consensus target price of $178.57.
Check Out Our Latest Report on RGEN
Repligen Company Profile
Repligen Corporation (NASDAQ:RGEN) develops and manufactures bioprocessing technologies used in the production of biological medicines. Its products support key stages of biopharmaceutical manufacturing, including upstream processing, downstream purification, filtration, process monitoring and fluid management.
The company’s offerings include chromatography products, filtration systems, single-use technologies, process analytics equipment and critical biological materials such as recombinant proteins.
See Also
- Five stocks we like better than Repligen
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN – Free Report).
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.
